* Sarepta Therapeutics Inc reported quarterly adjusted earnings of 37 cents per share for the quarter ended in March, higher than the same quarter last year, when the company reported EPS of $-5.86. The mean expectation of twenty one analysts for the quarter was for a loss of 7 cents per share. Wall Street expected results to range from -64 cents to 36 cents per share.
* Revenue rose 63.1% to $413.46 million from a year ago; analysts expected $377.78 million.
* Sarepta Therapeutics Inc shares had fallen by 2.2% this quarter and gained 31.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 444.7% in the last three months.
* In the last 30 days, five analysts negatively revised earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Sarepta Therapeutics Inc is $166.00 This summary was machine generated from LSEG data May 1 at 09:22 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.07 0.37 Beat
Dec. 31 2023 0.01 0.47 Beat
Sep. 30 2023 -1.23 -0.46 Beat
Jun. 30 2023 -1.78 -0.27 Beat
Comments